The 48-hour window for antivirals comes from trials in otherwise healthy outpatients, where the benefit is shortening symptoms. It does not apply to patients who are admitted, severely ill or at high risk of complications.
For these patients, IDSA and CDC guidance advise starting oseltamivir as soon as influenza is suspected, whenever symptoms began and without waiting for a test result. Observational data associate even late treatment with lower mortality in hospitalised patients.
- Admitted patient with suspected influenza: start oseltamivir now
- High-risk outpatient: treat regardless of symptom duration
- Do not wait for PCR results in severe illness
- Adjust the dose for reduced kidney function
Why it matters
Misapplying the 48-hour rule withholds treatment from the patients most likely to benefit.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free